Table 6, Recommended first-line cytotoxic drug

Eva Kassi; Anna Angelousi; George Zografos; Gregory Kaltsas; George Chrousos

Article2013

Table 2, Recommended sources of grey literature for conventional drugs and devices

Howard Balshem, Adrienne Stevens, Mohammed Ansari, Susan L. Norris, Devan Kansagara, Tatyana Shamliyan, Roger Chou, Mei Chung, David Moher, Kay Dickersin

Article2016

The Community As the Patient in Malaria-Endemic Areas: Preempting Drug Resistance with Multiple First-Line Therapies

Maciej F. Boni, Sir Nicholas White, J. Kevin Baird

PLoS Medicine

Article1995

Synthesis and cytotoxic activity of 6-vinyl- and 6-ethynyluridine and 8-vinyl- and 8-ethynyladenosine

Stefano Manfredini, Pier Giovanni Baraldi, Rita Bazzanini, Mirella Marangoni, Daniele Simoni, Jan Balzarini, De Clercq Erik

Article2011

Abstract 8440: Guideline Recommended Evaluation in Patients with a First Episode of Atrial Fibrillation

Moritz F. Sinner, Melissa A. Greiner, Xioajuan Mi, Adrian F. Hernandez, Paul N. Jensen, Jonathan Piccini, Soko Setoguchi, Allan J. Walkey, Susan R. Heckbert, Emelia Benjamin, Lesley H. Curtis

Article2009

First-line bortezomib benefits patients with multiple myeloma

Meletios A Dimopoulos, Evangelos Terpos

Table 6, Recommended first-line cytotoxic drug

Discussion(0)

Related publications

Table 2, Recommended sources of grey literature for conventional drugs and devices

The Community As the Patient in Malaria-Endemic Areas: Preempting Drug Resistance with Multiple First-Line Therapies

Synthesis and cytotoxic activity of 6-vinyl- and 6-ethynyluridine and 8-vinyl- and 8-ethynyladenosine

Abstract 8440: Guideline Recommended Evaluation in Patients with a First Episode of Atrial Fibrillation

First-line bortezomib benefits patients with multiple myeloma